Weight Loss Injections on the NHS

 

Tirzepatide, also known as Mounjaro®, is a GLP1/GIP agonist. Other medications such as semaglutide (Wegovy®), liraglutide (Saxenda®), are known as GLP-1 agonists. Both types of drug work in the same way and mimic gut hormones released by the body after eating, telling the brain you are full and slowing down the time it takes the stomach to empty.

23 June 2025 will see the beginning of access to the drug tirzepatide (Mounjaro®) for the management of obesity in primary care settings to eligible patients.

Tirzepatide (Mounjaro®) will not be accessible to everyone who wishes to use it. People with the highest health risks and who meet the clinical criteria will be prioritised.

From 23 June 2025, people who meet the qualifying criteria, will be able to gain access to the drug, if both patient and clinician agree it is the most appropriate treatment option.

Full qualifying criteria

Full qualifying criteria is a BMI (Body Mass Index) of 40 plus and four or more of the following diagnosed health conditions:

  • type 2 diabetes – on 2+ medications
  • high blood pressure – on medication
  • heart disease – on medication
  • obstructive sleep apnoea – using CPAP or similar
  • abnormal blood fats (dyslipidaemia) – on medication e.g. a statin

‘Access’ on 23 June does not mean people will be able to get a prescription for tirzepatide (Mounjaro) on that day. People living with obesity who meet the criteria will be able to explore with their healthcare professional whether this is the right treatment for them.

We will be sending out email/SMS questionnaires to get up to date health information to see who may be eligible.

Access to tirzepatide (Mounjaro®) in SE London will be via the Tier 3 Weight Management service based at Guys hospital. Access to the drug will be accompanied by wraparound care which will include support for people to make dietary changes and to increase physical activity.

Published: Jun 23, 2025